Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDANT Trial: BI 771716 vs Pegcetacoplan in Geographic Atrophy
NCT06722157Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Oct 2026
- Countries
- 1
- Sponsor
- Boehringer Ingelheim
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- BI 771716
- Conditions
- geographic atrophy (GA)
01
Overview
Phase 2, randomised, double-blind trial of BI 771716 in geographic atrophy (GA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Slope of change from baseline in square root transformed geographic atrophy area at 56 weeks. Started Jan 2025; status: active, not recruiting.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Arm A: BI 771716
BI 771716
Arm B: BI 771716 and Sham comparator
BI 771716 and Sham comparator
Arm C: Pegcetacoplan
Pegcetacoplan
03
Who it enrols
Participants must be >=50 years old with geographic atrophy secondary to AMD, total GA lesion area >=2.5 mm2 and <=17.5 mm2, and BCVA >=24 letters.
04
Endpoints
Primary
Slope of change from baseline in square root transformed geographic atrophy area
Secondary
Change from baseline in square root transformed geographic atrophy area
Change from baseline in best corrected visual acuity
Occurrence of BCVA letter loss of >=15 letters
Occurrence of exudative neovascular age-related macular degeneration
Occurrence of drug-related adverse events
Beyond the preview
Go deeper on NCT06722157.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722157.